Disney Stock Before Q3 Earnings: Buy Now or Wait for Results?
The Zacks Consensus Estimate for revenues is pegged at $23.67 billion, suggesting modest growth of 2.23% from the year-ago quarter's reported figure.
The consensus mark for earnings has moved south by a penny to $1.47 per share over the past 30 days, indicating growth of 5.76% year over year.
In the last reported quarter, Disney delivered an earnings surprise of 22.88%. The company's earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 16.38%.
The Walt Disney Company Price and EPS Surprise
The Walt Disney Company price-eps-surprise | The Walt Disney Company Quote
Earnings Whispers for DIS
Our proven model does not predict an earnings beat for Disney this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
DIS has an Earnings ESP of -0.61% and a Zacks Rank #2 at present. You can see the complete list of today's Zacks #1 Rank stocks here.
Factors Shaping Upcoming Results
As Disney approaches its third-quarter fiscal 2025 earnings report, several compelling positive factors suggest that investors should anticipate strong results that build on the company's exceptional momentum from recent quarters, creating a buy opportunity ahead of results.
Disney's Entertainment segment demonstrated remarkable resilience in the fiscal second quarter, with the segment generating $1.3 billion in operating income, representing a substantial 61% increase year over year. This momentum is expected to have carried forward into the fiscal third quarter as Disney+ launched its always-on perks program in May 2025, providing exclusive offers designed for subscribers and enhancing the customer value proposition.
The company's direct-to-consumer segment generated $336 million in operating income in the fiscal second quarter, up dramatically from $47 million a year earlier, with this profitability trend expected to accelerate through the quarter under review as integration efforts between Hulu and Disney+ delivered enhanced user engagement and reduced churn rates.
Our model estimates for Entertainment revenues (which include Linear Networks, Direct-to-Consumer and Content Sales/Licensing and Other Revenues) are pegged at $10.84 billion, indicating an increase of 2.5% year over year, driven by continued streaming subscriber growth and improved monetization strategies. Disney+ gained 1.4 million subscribers in the fiscal second quarter while Hulu added 1.3 million subscribers, establishing positive momentum that carried into the to-be-reported quarter amid successful content releases and enhanced user experiences.
The Sports segment benefited from ESPN's domestic advertising revenues growing 29% year over year in the fiscal second quarter, with preparations for the ESPN direct-to-consumer flagship service launch creating additional revenue opportunities. ESPN's SportsCenter launched its ambitious 50 States in 50 Days initiative, driving viewership and advertiser engagement that is expected to have enhanced fiscal third-quarter performance.
The Experiences segment positioned itself for exceptional third-quarter results following Disney's groundbreaking announcement in May 2025 of its seventh theme park resort in Abu Dhabi, United Arab Emirates, representing the company's first Middle East expansion. This waterfront resort on Yas Island will combine Disney's iconic stories with Abu Dhabi's vibrant culture, accessing one-third of the world's population within a four-hour flight radius. Disney Parks generated nearly $67 billion for the U.S. economy while supporting more than 400,000 U.S. jobs, demonstrating the segment's robust economic impact and growth potential.
Our model estimate for the Experiences segment (renamed from Disney Parks, Experiences and Products) revenues is $8.4 billion, indicating marginal growth of 0.3% year over year.
Disney delivered strong consolidated second-quarter fiscal 2025 results with 20% growth in adjusted earnings per share and 7% growth in revenues to $23.6 billion. Management's optimistic guidance for high-single digit adjusted EPS growth for fiscal 2025 appears increasingly achievable given the multiple positive catalysts converging in the fiscal third quarter, positioning DIS for another quarter of robust financial performance across all business segments.
Price Performance & Stock Valuation
Shares of Disney have returned 4.7% in the year-to-date period compared with the Zacks Consumer Discretionary sector's growth of 6.3%. Disney operates in a fiercely competitive streaming market dominated by the likes of Amazon AMZN -owned Amazon Prime Video and Netflix NFLX, as well as the growing prominence of services from Apple AAPL, Peacock and HBO Max. While Apple and Amazon has lost 19.2% and 2.1% year to date, respectively, shares of Netflix have returned 30%.
Disney's Year-to-Date Performance
Valuation-wise, Disney trades at a forward P/E of approximately 18.61x despite achieving streaming profitability and executing massive expansion plans, notably below the Zacks Media Conglomerates industry average of 20.25x.
DIS' P/E F12M Ratio Depicts Discounted Valuation
Investment Considerations Ahead of Q3 Results
Disney presents a compelling buy opportunity ahead of third-quarter fiscal 2025 earnings, trading at an attractive discount despite multiple catalysts driving growth acceleration. The company's streaming profitability surged to $336 million in operating income, a groundbreaking Abu Dhabi theme park expansion, and access to one-third of the global population, and $63 billion licensing dominance positioning Disney advantageously against the competition. While rivals struggle with streaming losses, Disney's integrated ecosystem of Disney+, Hulu, and ESPN creates sustainable competitive moats. Strong second-quarter momentum with 20% adjusted EPS growth, robust theme park performance, and ESPN's advertising revenues surging 29% establishes powerful fundamentals supporting significant upside potential at current valuations.
Final Thought
Disney's convergence of streaming profitability, international expansion, and robust operational momentum creates an exceptional investment opportunity at current valuations. With multiple growth catalysts accelerating and fiscal third-quarter results positioned to exceed expectations, investors should capitalize on this discounted entry point before markets fully recognize Disney's transformed business fundamentals and earnings potential.
Zacks Names #1 Semiconductor Stock
This under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Amazon.com, Inc. (AMZN): Free Stock Analysis Report
Apple Inc. (AAPL): Free Stock Analysis Report
Netflix, Inc. (NFLX): Free Stock Analysis Report
The Walt Disney Company (DIS): Free Stock Analysis Report
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
29 minutes ago
- Globe and Mail
Essential Thrombocythemia Pipeline Outlook Report 2025: Key 6+ Companies and Breakthrough Therapies Shaping the Future Landscape
DelveInsight's, 'Essential Thrombocythemia Pipeline Insight 2025' report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Essential Thrombocythemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Essential Thrombocythemia Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ Essential Thrombocythemia Pipeline Outlook Report In August 2025:- Icahn School of Medicine at Mount Sinai conducted a phase II study to assess the efficacy, safety, and tolerability of Reparixin in patients with DIPSS intermediate-2, or high-risk primary Essential Thrombocythemia (PMF), post essential thrombocythemia/polycythemia vera related MF (Post ET/PV MF) after prior treatment, and those who are ineligible or refuse treatment, with a Janus kinase inhibitor (JAKi). 26 patients will be enrolled. Eligible patients will receive oral reparixin three times daily on a 4-week cycle for a core study period of 6 cycles (24 weeks). DelveInsight's Essential Thrombocythemia pipeline report depicts a robust space with 6+ active players working to develop 6+ pipeline therapies for Essential Thrombocythemia treatment. The leading Essential Thrombocythemia Companies such as PharmaEssentia, Imago BioSciences, Novartis, Constellation Pharmaceuticals and others. Promising Essential Thrombocythemia Pipeline Therapies such as Anagrelide, Hydroxyurea, IMG-7289, Bomedemstat, Busulfan, Thromboreductin, Ropeginterferon alfa-2b-njft (P1101) and others. Discover how the Essential Thrombocythemia treatment paradigm is evolving. Access DelveInsight's in-depth Pipeline Analysis for a closer look at promising breakthroughs @ Essential Thrombocythemia Clinical Trials and Studies Essential Thrombocythemia Emerging Drugs Profile Ropeginterferon alfa-2b: PharmaEssentia Ropeginterferon alfa-2b is a novel, long-acting, mono-pegylated proline interferon (ATC L03AB15). Its pharmacokinetic properties offer a new level of tolerability. Ropeginterferon alfa-2b is designed to be self-administered subcutaneously with a pen once every two weeks, or monthly during long-term maintenance. This treatment schedule is expected to lead to overall better safety, tolerability and adherence compared to conventional pegylated interferons. PharmaEssentia Corporation is developing a pegylated (PEG) IFN-α product, P1101, for the treatment of ET. The Phase III multi-site, open-label, randomized, active-controlled study will compare the efficacy, safety, and tolerability and pharmacokinetics of P1101 as second line therapy for ET as compared with anagrelide, a commonly used oral platelet-reduction therapy. IMG-7289: Imago Biosciences IMG-7289 (Bomedemstat) is an orally available small molecule, discovered and developed by Imago BioSciences that inhibits lysine-specific demethylase 1 (LSD1 or KDM1A), an enzyme shown to be vital in cancer stem/progenitor cells, particularly neoplastic bone marrow cells. In non-clinical studies, bomedemstat demonstrated robust in vivo anti-tumor efficacy across a range of myeloid malignancies as a single agent and in combination with other therapeutic agents. The drug is being evaluated in Phase II clinical trial to treat patients with Essential thrombocythaemia, Essential Thrombocythemia, and Polycythaemia Vera. The Drug has been granted orphan and fast track designation from US FDA. The Essential Thrombocythemia Pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Essential Thrombocythemia with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Essential Thrombocythemia Treatment. Essential Thrombocythemia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Essential Thrombocythemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Essential Thrombocythemia market. Get a detailed analysis of the latest innovations in the Essential Thrombocythemia pipeline. Explore DelveInsight's expert-driven report today! @ Essential Thrombocythemia Unmet Needs Essential Thrombocythemia Companies PharmaEssentia, Imago BioSciences, Novartis, Constellation Pharmaceuticals and others. Essential Thrombocythemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Parenteral Intravenous Subcutaneous Topical Molecule Type Essential Thrombocythemia Products have been categorized under various Molecule types such as Monoclonal Antibody Peptides Polymer Small molecule Gene therapy Product Type Download DelveInsight's latest report to gain strategic insights into upcoming Essential Thrombocythemia Therapies and key Developments @ Essential Thrombocythemia Market Drivers and Barriers, and Future Perspectives Scope of the Essential Thrombocythemia Pipeline Report Coverage- Global Essential Thrombocythemia Companies- PharmaEssentia, Imago BioSciences, Novartis, Constellation Pharmaceuticals and others. Essential Thrombocythemia Pipeline Therapies- Anagrelide, Hydroxyurea, IMG-7289, Bomedemstat, Busulfan, Thromboreductin, Ropeginterferon alfa-2b-njft (P1101) and others. Essential Thrombocythemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Essential Thrombocythemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in Essential Thrombocythemia drug development? Find out in DelveInsight's exclusive Essential Thrombocythemia Pipeline Report—access it now! @ Essential Thrombocythemia Emerging Drugs and Major Companies Table of Contents Introduction Executive Summary Essential Thrombocythemia: Overview Pipeline Therapeutics Therapeutic Assessment Late Stage Products (Phase III) Ropeginterferon alfa-2b: PharmaEssentia Mid Stage Products (Phase II) IMG-7289: Imago Biosciences Early stage products (Phase I/II) Drug Name: Company Name Inactive Products Essential Thrombocythemia Key Companies Essential Thrombocythemia Key Products Essential Thrombocythemia- Unmet Needs Essential Thrombocythemia- Market Drivers and Barriers Essential Thrombocythemia- Future Perspectives and Conclusion Essential Thrombocythemia Analyst Views Essential Thrombocythemia Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
29 minutes ago
- Globe and Mail
Do Options Traders Know Something About Royal Gold Stock We Don't?
Investors in Royal Gold, Inc. RGLD need to pay close attention to the stock based on moves in the options market lately. That is because the Dec. 19, 2025 $70 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy. What do the Analysts Think? Clearly, options traders are pricing in a big move for Royal Gold shares, but what is the fundamental picture for the company? Currently, Royal Gold is a Zacks Rank #1 (Strong Buy) in the Mining – Gold industry that ranks in the Top 21% of our Zacks Industry Rank. Over the last 30 days, no analyst increased the earnings estimates for the current quarter, while one has dropped the estimates. The net effect has taken our Zacks Consensus Estimate for the current quarter from $1.65 per share to $1.70 in that period. Given the way analysts feel about Royal Gold right now, this huge implied volatility could mean there's a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected. Looking to Trade Options? Check out the simple yet high-powered approach that Zacks Executive VP Kevin Matras has used to close recent double and triple-digit winners. In addition to impressive profit potential, these trades can actually reduce your risk. Zacks Names #1 Semiconductor Stock This under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Royal Gold, Inc. (RGLD): Free Stock Analysis Report
CBC
29 minutes ago
- CBC
Yellowknife residents gather for the weekend at Old Town Ramble and Ride
Clear skies and good company set the tone for the 19th annual Ramble and Ride festival in Yellowknife's Old Town this weekend. The event drew a bustling crowd, with residents soaking up the sunshine on Saturday and taking in everything from textile art exhibits to street food vendors. The festival went ahead this year, despite wildfire smoke blanketing much of the territory on Friday. Air quality advisories were issued for several N.W.T. communities, but the advisory in Yellowknife was lifted in time Saturday's events. "Well, actually, when I woke up [Saturday] morning, I went for my dog walk like I usually do every morning, and it didn't register that the sky was bright blue," said Gigi Forget, a vendor at the festival. "Then I got here and somebody pointed out that the sky is clear and visible. And I was like, 'Oh my God, yes, it is. I can see the clouds.'" Forget said the warm weather made it all the more enjoyable to connect with the community. "Well, I just think if people could be more grateful for what's around us and what we have in our lives, I think that's necessary. And it's a beautiful thing you wake up and just be grateful to be breathing and have people that you can love." Nearby, a group of textile artists were showing off their latest creative challenge in a mobile exhibit space, with six artists contributing to a circular art piece series they'd been planning for months. Pat Moore and Hazel Wainwright, both members of the Yellowknife Guild of Arts and Crafts, displayed their work made using wool paper, velvet, sequins, and other materials. "So I did this with what's called wool papers…When you layer them, you can see that the colours come through. That was quite fun," said Moore. Earlier this year, the group met between Christmas and New Year's at the Guild to plan their pieces. One of the younger members pushed for a new challenge, which led them to the circular theme, a first for many of the artists. The group's pieces were housed in a mini art trailer that they've brought to the festival for the past few years. "It's a perfect size for the group," Moore said. "It's always fun to come and set up and see things." Moore was pleased with the turnout at this year's event. "It's great because I thought if it's really smoky, people won't come out and see all the work that goes into getting ready for all the vendors [and] all the volunteers for Ramble and Ride." The Ramble and Ride festival wrapped up on Sunday evening.
